Panbela announces acceptance of abstract for poster presentation at american society of clinical oncology annual meeting

Minneapolis, april 06, 2021 (globe newswire) -- panbela therapeutics, inc. (nasdaq: pbla), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announced that an abstract for sbp-101, a proprietary polyamine analogue, has been accepted for poster presentation at the american society of clinical oncology (asco) annual meeting, which will be held virtually from june 4-8, 2021.
PBLA Ratings Summary
PBLA Quant Ranking